

EMA/579333/2022

European Medicines Agency decision

P/0249/2022

of 8 July 2022

on the acceptance of a modification of an agreed paediatric investigation plan for garadacimab (EMA-002726-PIP01-19-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0249/2022

of 8 July 2022

on the acceptance of a modification of an agreed paediatric investigation plan for garadacimab (EMA-002726-PIP01-19-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0451/2020 issued on 1 December 2020 and the decision P/0274/2021 issued on 8 July 2021,

Having regard to the application submitted by CSL Behring GmbH on 18 February 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 May 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for garadacimab, solution for injection, subcutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to CSL Behring GmbH, Emil-von-Behring-Strasse 76, 35041 - Marburg, Germany.

EMA/PDCO/128471/2022
Amsterdam, 20 May 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002726-PIP01-19-M02

Scope of the application

Active substance(s):

Garadacimab

Condition(s):

Prevention of hereditary angioedema attacks

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

CSL Behring GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, CSL Behring GmbH submitted to the European Medicines Agency on 18 February 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0451/2020 issued on 1 December 2020 and the decision P/0274/2021 issued on 8 July 2021.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 21 March 2022.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Prevention of hereditary angioedema attacks

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Prevention of hereditary angioedema attacks

2.1.1. Indication(s) targeted by the PIP

Routine prevention of hereditary angioedema attacks

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality	Study 1 Development of a 100mg pre-filled syringe in order to obtain an appropriate 1ml dose for use in the paediatric population from 2 to less than 12 years of age
Non-clinical studies	Not applicable
Clinical studies	Study 2 Double-blind, randomized, placebo-controlled, parallel-arm, confirmatory study to evaluate the pharmacokinetics, safety and efficacy of garadacimab when administered as a prophylaxis in in adolescents from 12 to less than 18 years of age (and adults) with hereditary angioedema (HAE), (CSL312_3001)

	Study 3 Open label, single-arm, intra-patient controlled study to evaluate the long-term safety and efficacy of garadacimab when administered as a prophylaxis in adolescents from 12 to less than 18 years of age (and adults) with hereditary angioedema (HAE), (CSL312_3002) Study 4 Open label, intra-patient controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of garadacimab when administered as a prophylaxis in children from 2 to less than 12 years of age with hereditary angioedema (HAE)
Extrapolation, modelling and simulation studies	Study 5 Population pharmacokinetic modelling and analyses to describe the pharmacokinetics of garadacimab in adolescent patients from 12 to less than 18 years of age and adults with hereditary angioedema Study 6 Analysis of existing in-house exposure data to supporting the extrapolation of PK from adult and adolescent subjects to paediatric subjects from 2 to less than 12 years of age with hereditary angioedema and inform dose selection for paediatric subjects from 2 to less than 12 years of age
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes